Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Saved in:
Bibliographic Details
Title: Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Authors: Brown, J. R.1 jennifer_brown@dfci.harvard.edu, Eichhorst, B.2, Hillmen, P.3, Jurczak, W.4, Kaźmierczak, M.5, Lamanna, N.6, O'Brien, S. M.7, Tarn, C. S.8,9, Qiu, L.10, Zhou, K.11, Simkovic, M.12,13, Mayer, J.14, Gillespie-Twardy, A.15, Ferrajoli, A.16, Ganly, P. S.17, Weinkove, R.18, Grosicki, S.19, Mitai, A.20, Robak, T.21, Osterborg, A.22,23
Source: New England Journal of Medicine. 1/26/2023, Vol. 388 Issue 4, p319-332. 14p.
Database: Academic Search Ultimate
Description
ISSN:00284793
DOI:10.1056/NEJMoa2211582